Novel endopeptidase overcoming lysostaphin resistance Authors: Piotr Henryk Małecki, Karolina Trochimiak, Elżbieta Jagielska, Michał Zaród, Małgorzata Korzeniowska née Wiweger, Weronika Augustyniak, Izabela Sabała Published: 2026 ABSTRACT AbstractThis study reports the discovery and characterization of a novel enzyme, LssR, a member of the M23 family of peptidoglycan hydrolases from Staphylococcus simulans. Three variants of LssR: the full-length protein (LssR_FL), the mature form (LssR_M), and the catalytic domain (LssR_CD) were cloned, overexpressed in a heterologous E. coli system, and purified. The bacteriolytic activities of these variants were systematically evaluated, and optimal conditions were established for each of them. Notably, all variants exhibited robust bacteriolytic activity against live staphylococcal cells, including strains with serine-containing cross-bridges, that typically confer resistance to lysostaphin. To our knowledge, this is the first report of a novel endopeptidase cleaving serine-containing cross-bridges in staphylococcal peptidoglycan, underscoring potential of LssR as a promising antimicrobial agent capable of overcoming possible lysostaphin resistance.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-026-43937-3.Keywords: Lysostaphin, Staphylococcus aureus, Peptidoglycan hydrolase, M23 peptidaseSubject terms: Biotechnology, Microbiology Introduction Staphylococcus aureus and certain other staphylococcal species are pathogenic bacteria that infect humans and other mammals, causing a wide range of diseases, including skin and ocular infections, pneumonia, meningitis, endocarditis, osteomyelitis, and food poisoning. These pathogens are frequently isolated from vascular and foreign body-related medical samples. In addition to forming biofilms that invade tissues, they serve as reservoirs of drug resistance genes1. The increasing prevalence of staphylococci carrying resistance genes and the challenges in treating these infections with existing antibiotics underscore the urgent need for novel antimicrobial agents effective against this group of bacteria. Since the discovery of penicillin in 1928, the history of antibiotic development has been marked by rapid bacterial adaptation, as predicted by Alexander Fleming’s assertion: “There is probably no chemotherapeutic drug to which in suitable circumstances the bacteria cannot react by in some way acquiring ‘fastness’ [resistance]”2. In many cases, resistance emerges within a few years after the introduction of a new antibiotic3. As an alternative to low molecular weight therapeutics, the discovery of lysostaphin (Lss) opened new avenues for antimicrobials’ development based on bacteriolytic enzymes4, 5, 6. Lysostaphin, a peptidoglycan hydrolase from Staphylococcus simulans biovar staphylolyticus, belongs to the M23 family (MEROPS)7. Lss effectively lyses the cell walls of S. aureus and other staphylococci, including antibiotic-resistant strains, through its specific glycyl-glycine endopeptidase activity. This activity targets the pentaglycine cross-bridges in staphylococcal peptidoglycan (PGN)8. M23 enzymes are metallopeptidases, whose activity relies on a Zn²⁺ ion coordinated by two histidine residues and one aspartic acid residue, forming the conserved motifs: HxxxD and HxH. Structurally, lysostaphin consists of an N-terminal signal peptide, a propeptide, a catalytic domain (CD), cell wall-targeting domain (CWT), and a flexible linker connecting the CD with CWT9. In the context of antimicrobial resistance (AMR), the ability of lysostaphin to degrade bacterial cell walls through a mechanism distinct from traditional antibiotics has made it a strong candidate for treating staphylococcal infections10, 11. Furthermore, lysostaphin has demonstrated efficacy against biofilm-forming S. aureus, a common feature of chronic infections, that is notoriously difficult to treat with conventional antibiotics12, 13. The antimicrobial potential of lysostaphin has been evaluated in various medical applications showing high efficacy4, 5. The narrow spectrum, targeting only Staphylococcus species, contrasts with the broad-spectrum effects of traditional antibiotics, which can disrupt normal microbiota, and contribute to dysbiosis. Beyond its therapeutic potential, lysostaphin has attracted interest in various biotechnological applications. Its bacteriolytic activity has been explored for food preservation, controlling Staphylococcus contamination in dairy products and meat11. It has also been investigated as a biocontrol agent in agriculture to manage Staphylococcus contamination in plant and animal systems, offering an eco-friendly alternative to chemical treatments5. Despite its promising properties, several challenges hinder the full exploitation of lysostaphin in the therapeutic and industrial contexts. Issues such as enzyme stability, delivery strategies, and large-scale production need to be addressed to make lysostaphin a viable alternative to antibiotics. Notably, major concern is the potential development of resistance. As a bacteriocin, lysostaphin allows S. simulans to eliminate competing bacteria within its niche. To avoid self-destruction, S. simulans employs a self-immunity mechanism mediated by the epr gene (also known as lif—lysostaphin immunity factor). This gene facilitates the incorporation of serine instead of glycine in the pentapeptide cross-bridges of its PGN14. The genes encoding lysostaphin and its immunity factor are plasmid-borne allowing horizontal transfer to other staphylococcal strains and thereby facilitating the spread of resistance. Experimentally, S. aureus strains harbouring the epr gene display approximately tenfold reduced susceptibility to lysostaphin15. This plasmid-mediated mobility of the resistance gene increases the likelihood of resistance development, which has already been demonstrated in vitro16. In this study, we describe the discovery and characterization of a novel lysostaphin-like peptidoglycan hydrolase, named LssR. Unlike lysostaphin, LssR is chromosomally encoded in S. simulans. The lssR gene was cloned, and the protein was expressed, purified, and comprehensively characterized. LssR exhibits potent antistaphylococcal activity and importantly, retains activity against bacterial cell walls containing serine-substituted cross-bridges. Additionally, LssR shows activity over a broad range of pH and ionic strength remaining effective in serum, highlighting its potential as a novel antimicrobial agent. Importantly, our biological assays demonstrated that LssR is not cytotoxic and not teratogenic, suggesting its potential for safe therapeutic use in humans and animals. Results Protein identification This study aimed to identify and characterize an endopeptidase with the unique activity against staphylococci that incorporate serine residue into their peptidoglycan cross-bridges as a mechanism of the resistance to such enzymes. A search for homologues of lysostaphin was performed within the genome of S. simulans DSM203228. An NCBI BLASTP search identified the gene (accession no. KXA44996.1) encoding a 424-amino acid long protein. This protein comprises an N-terminal signal peptide, a propeptide sequence, catalytic domain, and a C-terminal cell wall targeting (CWT) domain (Fig. 1A and B). (A) Schematic representation of the domain organization in the LssR protein. Domains are depicted as boxes and labelled according to their predicted functions: signal peptide (SP), N-terminal domain (ND), catalytic domain (CD), linker (L), and cell wall targeting domain (CWT). Approximate domain boundaries are indicated by amino acid positions. Constructs designed for this study are shown below and labeled as follows: LssR_FL (full-length protein), LssR_CD (catalytic domain), and LssR_M (mature form). (B) Sequence alignment of LssR and lysostaphin in the CD, L, and CWT regions. Conserved motifs characteristic of M23 family proteins within the CD: HxxxD and HxH, which coordinate the catalytic zinc ion, are highlighted with blue and yellow backgrounds, respectively. The presence of the N-terminal signal peptide suggests extracellular localisation of the protein17. The propeptide, that in other peptidases plays inhibitory role, shows no significant sequence similarity to any other known protein. The CD domain belongs to the MEROPS M23 family of Zn2+ dependent endopeptidases with characteristic HxxxD and HxH motifs essential for zinc binding and enzymatic activity18, 19. The C-terminal CWT domain is classified as a member of SH3b family20, 21, 22. Sequence alignment revealed that the CD of this novel protein shares 68% amino acid sequence identity with lysostaphin (Lss), while the C-terminal CWT domain shares 73% identity. Comparison of the LssR AlphaFold model to the structure of lysostaphin confirmed high structural similarity between these two proteins, in their catalytic and cell wall binding domains (Fig. S1). Based on its similarity to lysostaphin, and potential activity against lysostaphin-resistant bacterial strains, this newly identified protein was named LssR. Locus organization The locus of the gene encoding LssR (accession no. KXA44996.1) in S. simulans genome was analysed using an operon analysis tool18. The gene is co-localized with two others encoding protein IS1272 (upstream) and FmHA-like protein (downstream). The analysis suggests that the lssR gene and an adjacent gene encoding an aminoacyltransferase FmhA-like protein are co-transcribed. The FmhA belongs to the family of nonribosomal peptidyl transferases responsible for building the PGN cross-bridges and determining their length and amino acid composition. FmhA-like protein shares 67% amino acid sequence identity with S. aureus FmhA, which is known to incorporate serine residues at position 3 and/or 5 of the cross-bridge19. This gene arrangement is analogous to the lysostaphin operon, in which lss is co-transcribed with its immunity factor, epr23. Similarly, the gene encoding the peptidoglycan hydrolase Zoocin A (zooA) from Streptococcus zooepidemicus is transcribed alongside its immunity factor24. Both the lss and zooA genes are flanked by transposon-like sequences. Notably, a gene encoding transposase family protein IS1272 was identified downstream of the lssR gene, suggesting that horizontal gene transfer may have contributed to the acquisition of such hydrolase systems25, 26(Fig. S2). Cloning and initial protein purification Initial small-scale purifications of the three protein variants were performed to assess the expression levels and solubility. Both LssR_FL (full-length LssR) and LssR_M (mature LssR) were successfully expressed and purified in soluble form. SDS-PAGE analysis showed sharp bands at molecular weights corresponding to their theoretical values: 44.6 kDa for LssR_FL (42.1 kDa after TEV protease cleavage) and 30.6 kDa for LssR_M (28.1 kDa after TEV cleavage) (Fig. S3 A and B). In contrast, the LssR_CD (CD of LssR) variant was mainly produced as inclusion bodies, with only minimal amounts of soluble protein recovered. To improve solubility, LssR_CD was expressed as a fusion protein with maltose-binding protein (MBP), yielding a soluble product visible as a single band on SDS-PAGE consistent with its molecular weight of 57.7 kDa. Following cleavage of the MBP tag with TEV protease, the products were separated using size-exclusion chromatography. The resulting bands corresponded to the expected molecular weights of MBP (42.4 kDa) and LssR_CD (15.3 kDa) (Fig. S3 C-E). Further optimization of the purification buffers was guided by thermofluor shift assays which helped identify buffer compositions that enhanced protein stability and solubility (Fig. S4). LssR specificity First, we evaluaed whether generated protein variants exhibit enzymatic activity and are capable of lysing bacteria with serine containing cross-bridges in the peptidoglycan of their cell wall. Previous studies have shown that the activity of peptidoglycan hydrolases can be strongly affected by the presence of the N-terminal propeptide, that might play an inhibitory role, and by the buffering conditions of the reaction, particularly ionic strength27, 28. Therefore, initial activity tests were performed in two buffers: a low-ionic-strength buffer (50 mM glycine, pH 8.0) and a high-ionic-strength buffer (50 mM glycine, pH 8.0, 100 mM NaCl). Bacteriolytic activity was assessed by turbidity reduction assays using live S. aureus 8325-4 and S. simulans CCM3583 cells (Fig. 2). Bacteriolytic activity of LssR variants against S. aureus 8325-4 and S. simulans CCM3583 assessed by turbidity reduction assay. Optical density (OD595) reduction was measured after 60 min of incubation with 100 nM enzymes at 21°C, in 50 mM glycine buffer (pH 8.0) in the presence (+) or absence (-) of NaCl. Results are presented as a percentage of reduction of OD595 normalized to the control sample (cells incubated without enzyme). **** - P < 0.0001, two-way ANOVA with Sidak’s post-hoc multiple comparisons test. We were able to detect activity of all variants against both bacterial species tested. Both, the full-length protein (LssR_FL) and the mature form (LssR_M) displayed higher activity in the high-ionic-strength buffer. In contrast, the isolated CD (LssR_CD) exibited pronounced activity only under the low-ionic-strength conditions, and its activity was almost completely abolished in the presence of salt (Fig. 2). Overall, these results demonstrate that LssR variants retain potent bacteriolytic activity against staphylococcal strains containing either canonical pentaglycine cross-bridges or serine substituted cross-bridges in their peptidoglycan. To confirm that LssR is indeed a peptidoglycan hydrolase with endopeptidase activity, we performed a digestion experiment using purified peptidoglycan from S. aureus and S. simulans followed by mass spectrometry analysis of the reaction. Peptidoglycan was isolated from S. aureus NCTC 8325-4 (containing canonical pentaglycine cross-bridges) and S. simulans CCM3583 (containing cross-bridges composed of glycines and serines). Both PGN samples were first digested with mutanolysin to generate small-molecular-weight soluble substrates (muropeptides) for subsequent treatment with LssR. LssR_M treatment resulted in generation of fragments whose masses corresponded to cross-bridges cleaved peptidoglycan, regardless of the presence or absence of serine residues. Compared to the control samples treated with mutanolysin alone, UPLC chromatograms of LssR_M-treated samples showed a pronounced increase in the abundance of peaks corresponding to PGN monomers, accompanied by a marked decrease in peaks corresponding to intact cross-linked species (dimers, trimers, and tetramers) (Fig. 3). These results demonstrate that LssR functions as a peptidoglycan hydrolase with an endopeptidase activity and is capable of cleaving both glycine-only and glycine/serine-containing cross-bridges, however further MS/MS analysis would be required to clearly confirm the structure of the assigned peptidoglycan fragments. Separation of S. aureus NCTC 8325-4 (A) or S. simulans CCM3583 (B) peptidoglycan digestion products obtained after treatment with mutanolysin (gold) or with both mutanolysin and LssR_M (black). Peptidoglycans were treated with mutanolysin only for 24 h at 50°C in 50 mM glycine buffer, pH 8.0 or they were subsequently digested with LssR_M for 24 h at room temperature in the same buffer supplemented with 100 mM NaCl. Samples were separated by UPLC and analysed using a mass spectrometer. Panels show chromatograms demonstrating the separation of monomeric products from higher-molecular-weight peptidoglycan fragments. Schematic structures depict monomeric reaction products, based on the masses inferred from the obtained m/z spectra (Fig. S5, Tab. S2). To further characterize the substrate specificity of LssR, we performed activity assays against a range of bacterial species (Fig. 4). No lytic activity was detected against strains with direct peptidoglycan cross-linking, such as Bacillus subtilis and Corynebacterium spp. Likewise, strains possessing cross-bridges composed of short peptides, such as single D-Asp (Lactococcus lactis) or di-Ala (Streptococcus agalactiae) - were not lysed (Fig. 4). Bacteriolytic activity of LssR_M and LssR_CD against bacterial strains with different peptidoglycan cross-bridge compositions (indicated using single-letter amino acid code or as DIRECT – no cross-bridge). Turbidity reduction assays were performed by incubating bacterial cells with 100 nM of each enzyme for 1 h at 21°C in 50 mM glycine buffer (pH 8.0) alone for LssR_CD or supplemented with 100 mM NaCl for LssR_M. Enzyme activity is presented as the percentage of the reduction of the initial OD595 normalized to the negative control (cells incubated without enzyme). **** - P < 0.0001, ** - P < 0.01, * - P < 0.05, two-way ANOVA with Sidak’s post-hoc multiple comparisons test. We than assessed the activity of the LssR_CD and LssR_M enzyme variants on various staphylococcal species containing either pentaglycine or glycine/serine cross-bridges. Both enzyme variants exhibited robust bacteriolytic activity against all tested staphylococcal strains, with the exception of S. cohnii. Notably, S. cohnii was highly susceptible to LssR_CD, whereas its susceptibility to LssR_M was significantly reduced, indicating that other structural components of bacterial cell wall are involved in the regulation of the enzyme activity. To confirm that, within a single bacterial strain background, the presence of serine in the peptidoglycan cross-bridge does not affect LssR activity, we tested the S. aureus TF5303 strain, which contains a native pentaglycine cross-bridge, and its isogenic variant TF5311, which expresses the epr gene, leading to the incorporation of serine into the cross-bridge29. The obtained results confirmed that such modification in the peptidoglycan cross-bridge composition had only a minor impact on the efficiency of the tested enzymes (Fig. S6). To further investigate the possible role of other component of cell wall polymers, specifically wall teichoic acids (WTAs), WTA-depleted cells were generated by treating S. aureus TF5303 and S. aureus TF5311 cultures with tunicamycin, an inhibitor of teichoic acid biosynthesis30. Additionally, a WTA-deficient mutant strain, S. aureus RN4220ΔtagO, lacking the tagO gene essential for the initial step of WTA biosynthesis, was included in the study31. In turbidity reduction assay, WTA-depleted cells were as susceptible to the LssR_M enzyme as their parental strains (Fig. S6). However, the activity of the LssR_CD was significantly reduced against WTA-depleted cells, indicating high WTAs dependence of the CD activity. Lytic efficacy of LssR To further characterize the enzymes, we compared their activity with the well-known lysostaphin, which cleaves glycyl-glycine bonds in the staphylococcal peptidoglycan cross-bridges. For detailed antimicrobial characterization, the most active enzyme variants, LssR_CD and LssR_M, were selected. Antistaphylococcal activity was assessed using both, turbidity reduction and CFU reduction assays, with lysostaphin as the reference endopeptidase. The enzymes were tested against S. aureus 8325-4, which possesses pentaglycine cross-bridges, and S. simulans CCM3583, which incorporates both glycine and serine into its cross-bridges. Overall, all enzymes exhibited greater efficacy against S. aureus compared to S. simulans (Fig. 5). At a concentration as little as 50 nM LssR_CD was able to reduce S. aureus bacterial cell number from 108 to 104 CFU within one hour, whereas 100 nM LssR_CD completely eliminated 108 of S. aureus cells. To achieve comparable effects lysostaphin had to be applied at a concentration of 200 nM (Fig. 5). The activity of LssR_M was similar to that of lysostaphin and clearly depended on the enzyme concentration. Bacteria elimination by LssR_CD and LssR_M. A CFU reduction assay was performed on S. aureus 8325-4 and S. simulans CCM3583 using 50, 100 and 200 nM concentrations of LssR_CD, LssR_M, and Lss (used as a reference). Enzymes were incubated with bacterial cells (108 CFU/ml) for 2 h at 21°C in 50mM glycine buffer (pH 8.0) alone for Lss_CD or supplemented with 100mM NaCl for LssR_M and Lss. Colony-forming units (CFU) were quantified by serial dilution plating. **** - P < 0.0001, ** - P < 0.01, two-way ANOVA with Sidak’s post-hoc multiple comparisons test. The rapid bacteriolytic effect of the enzymes was also evident as indicated by 70–80% decrease in initial optical density within the first 10 min of incubation (Fig. 6). The bacteriolytic activity of LssR_CD and LssR_M. Turbidity reduction assays were performed on S. aureus 8325-4 and S. simulans CCM3583 using varying concentrations of LssR_CD, LssR_M, and Lss (used as a reference). Bacterial cells were incubated with the enzymes for 60 min at 21°C with shaking. C-, control, bacteria in glycine buffer (pH 8.0) used for LssR_CD, C+, bacteria in glycine buffer (pH 8.0) supplemented with 100 mM NaCl, used for LssR_M and Lss. *** - P < 0.001, ** - P < 0.01, * - P < 0.05, repeated measures ANOVA with Dunnett’s post-hoc multiple comparisons test with control samples without enzymes set as a control. All tested concentrations of LssR_CD led to approximately 85% reduction in initial OD595, and the effect was achieved after 20 min (Fig. 6). Similar fast turbidity reduction was observed for LssR_M, being slower only for the lowest, 50 nM enzyme concentration. Lysostaphin was also less efficient in the turbitiy reduction assay compared to tested LssR enzymes, even if applied in 200 nM concentration. In contrast to lysostaphin, both LssR_CD and LssR_M were highly active against S. simulans. At a concentration of 200 nM, LssR_CD reduced S. simulans cell counts from over 108 to approximately 104, while LssR_M decreased the initial bacterial cell count to 105 CFU. By comparison, lysostaphin exhibited negligible activity against S. simulans (Fig. 5). Turbidity reduction assays further revealed that although the lysis of S. simulans was slower than that of S. aureus, even at the highest concentrations, about half of the final decrease in optical density occurred within the first 10 min of incubation (Fig. 6). Notably, lysostaphin was confirmed to be uneffective in S. simulans elimination in both types of tests. These findings demonstrate that, unlike lysostaphin, both LssR_CD and LssR_M exhibit unique bacteriolytic activity against staphylococcal strains incorporating serine into their peptidoglycan cross-bridges. The effect of reaction conditions Ionic strength Previous studies have demonstrated that the activity of peptidoglycan hydrolases is influenced by the ionic strength of the buffer and that the presence of a cell wall-binding domain plays a critical role in modulating this activity27, 28. To explore this further, the activities of the catalytic domain (LssR_CD) and the mature enzyme (LssR_M) were tested under varying NaCl concentrations. Remarkably, LssR_CD could reduce the initial turbidity of a bacterial suspension by ~ 30% even in distilled water, with its activity increasing to over 70% in low-ionic-strength buffers such as 50 mM glycine buffer. However, its activity declined sharply as buffer conductivity exceeded 3 mS/cm and dropped to negligible levels above ~ 5 mS/cm, corresponding to roughly 50 mM NaCl. In contrast, the mature enzyme LssR_M, which includes the CWT domain, maintained robust activity even at the highest salt concentration tested (250 mM NaCl, ~ 20 mS/cm) (Fig. 7.) Effect of ionic strength on the lytic activity of LssR_M and LssR_CD enzymes. Turbidity reduction assays were performed using S. simulans CCM3583 cells suspended in 50 mM glycine buffer (pH 8.0) supplemented with increasing concentrations of NaCl to achieve varying ionic strengths. Values of buffers conductivity in µS/cm are indicated in gray. OD595 was measured after 45 min of incubation at 21°C. Enzyme activity is expressed as the percentage reduction in the initial OD₅₉₅ relative to the control without enzyme. **** - P < 0.0001, *** - P < 0.001, * - P < 0.05, two-way ANOVA with Sidak’s post-hoc multiple comparisons test. These findings highlight the essential role of the CWT domain in maintaining enzyme functionality under high-salt conditions and demonstrate the distinct functional properties of LssR_M compared to its CD alone. pH The effect of pH on the activity of LssR_M, LssR_CD, and lysostaphin (Lss) was assessed using S. simulans CCM3583 and S. aureus 8325-4 cells (Fig. 8). Lysostaphin maintained robust activity against S. aureus across a broad pH range of 7.0–10.0, a profile closely mirrored by LssR_M, which exhibited high activity within above mentioned pH range but additionally retained some activity also at lower and higher pH values. In contrast, for S. simulans lysis, LssR_M showed an optimal pH range more restricted to 7.0–8.0. The CD alone, LssR_CD, displayed activity over an even narrower pH range (pH 6.0–8.0) for both bacterial species (Fig. 8). These findings highlight the broader functional flexibility of LssR_M compared to its isolated CD, particularly under varying pH and ionic conditions (Fig. 8). The effect of pH on the activities of LssR_M, LssR_CD, and the reference enzyme lysostaphin (Lss) assessed by turbidity reduction assay. Enzyme activity was measured after 60 min of incubation with S. aureus 8325-4 and after 100 min with S. simulans CCM3583. Results are presented as the percentage of reduction of initial turbidity normalized to the negative control (bacterial suspension without enzyme). **** - P < 0.0001, *** - P < 0.001, ** - P < 0.01, * - P < 0.05, two-way ANOVA with Dunnett’s post-hoc multiple comparisons test with pH 8.0 set as a control. Ion chelators Protein sequence analysis classified LssR as a member of the M23 family of metalloproteases. As metal-dependent enzymes, M23 metalloproteases are known to be susceptible to ion-chelating agents32, 33. To evaluate this susceptibility, the activities of LssR_M and LssR_CD were tested in the presence of EDTA and phenanthroline (Fig. S7). The activity of LssR_M against S. aureus cells remained largely unaffected by EDTA concentrations up to 31 mM. Even at 125 mM EDTA, only a modest reduction in activity was observed, and complete inhibition was not achieved even at 250 mM. In contrast, when tested against S. simulans cells, inhibitory effect was evident starting from the lowest EDTA concentration tested. Similar trends were observed for LssR_CD. Phenanthroline displayed a significantly stronger inhibitory effect on both enzyme variants (Fig. S7). For LssR_M, full inhibition was observed at 2mM phenanthroline against S. aureus and at approximately 0.5 mM against S. simulans. Comparable inhibition profiles were recorded for LssR_CD (Fig. S7). These results demonstrate that LssR enzymes are considerably more sensitive to phenanthroline than to EDTA, and that the degree of inhibition depends on both the bacterial strain and the enzyme variant. Temperature We tested the influence of temperature on the lytic activity of LssR_M and LssR_CD. Both enzymes efficiently reduced the turbidity of S. aureus NCTC 8-3254 and S. simulans CCM3583 cell suspensions at 21°C. Enzyme activity increased further at 37°C and 45°C. In contrast, at 4°C the activity of both enzymes decreased noticeably, with a more pronounced reduction observed for S. simulans (Fig S8). The activity of the enzyme LssR_M in serum The mature enzyme, LssR_M, was evaluated alongside two well-known bacteriolytic enzymes active against S. aureus: lysostaphin (Lss) and AuresinePLUS, a chimeric enzyme combining the catalytic domain of LytM with the cell wall-binding domain of lysostaphin27. Lss_CD variant was excluded from these tests due to its lack of activity under higher ionic strength conditions, such as those present in serum. All three enzymes tested demonstrated comparable high efficiency in lysing S. aureus cells containing pentaglycine cross-bridges (Table 1). However, significant differences were observed when testing bacterial strains with serine-substituted cross-bridges. Both lysostaphin and the chimeric enzyme AuresinePLUS showed markedly reduced activity in glycine buffer, which declined further in the presence of serum. In contrast, the LssR_M enzyme retained robust staphylolytic activity against serine-containing S. aureus and S. simulans strains, maintaining effectiveness in both glycine buffer and serum. Interestingly, the effect of serum on enzyme activity varied depending on the serum source. For S. simulans, LssR_M exhibited very high activity in bovine and human serum but significantly lower activity in horse and rabbit serum. Notably, this variability was specific for S. simulans and was not observed with S. aureus strains (Table 1). Table 1Activity of LssR_M, Lss, and AuresinePLUS in the presence of serum from various sources. Bacterial cells (106 CFU/ml) were incubated with 100 nM of each enzyme for 4 h at 37°C. Enzyme activity was assessed by determining cell survival and presented as the log₁₀ reduction in initial cell number.Enzyme activityInitial cell number reduction (log10 CFU/ml (mean ± SD)S. aureus TF5303GGGGGS. aureus TF5311GGSGGS. simulans CCM3583GGSGG Glycine buffer Control (no enzyme)0.0 ± 0.00.0 ± 0.0-0.5 ± 0.7LssR_M6.0 ± 0.05.0 ± 1.46.0 ± 0.0Lysostaphin6.0 ± 0.03.5 ± 0.73.0 ± 0.0AuresinePLUS6.0 ± 0.05.0 ± 1.43.0 ± 0.0 Bovine serum Control (no enzyme)0.0 ± 0.00.0 ± 0.0-2.0 ± 0.0LssR_M6.0 ± 0.06.0 ± 0.06.0 ± 0.0Lysostaphin6.0 ± 0.02.0 ± 0.0-1.0 ± 0.0AuresinePLUS6.0 ± 0.02.0 ± 0.0-1.0 ± 0.0 Human serum Control (no enzyme)-1.0 ± 0.0-1.0 ± 0.0-1.0 ± 0.0LssR_M7.0 ± 0.07.0 ± 0.06.0 ± 0.0Lysostaphin7.0 ± 0.01.6 ± 0.50.3 ± 0.6AuresinePLUS7.0 ± 0.02.0 ± 0.00.3 ± 0.6 Horse serum Control (no enzyme)0.0 ± 0.00.0 ± 0.0-2.5 ± 0.7LssR_M6.0 ± 0.06.0 ± 0.01.0 ± 0.0Lysostaphin6.0 ± 0.02.0 ± 0.0-2.0 ± 0.0AuresinePLUS6.0 ± 0.02.0 ± 0.0-2.0 ± 0.0 Rabbit serum Control (no enzyme)-0.5 ± 0.7-0.5 ± 0.7-1.5 ± 0.7LssR_M6.0 ± 0.06.0 ± 0.73.0 ± 0.0Lysostaphin6.0 ± 0.00.5 ± 0.0-1.0 ± 0.0AuresinePLUS6.0 ± 0.01.0 ± 0.0-1.0 ± 0.0 Activity of LssR_M, Lss, and AuresinePLUS in the presence of serum from various sources. Bacterial cells (106 CFU/ml) were incubated with 100 nM of each enzyme for 4 h at 37°C. Enzyme activity was assessed by determining cell survival and presented as the log₁₀ reduction in initial cell number. Safety of LssR protein The potential toxicity of LssR_M was assessed both in vitro, using two mammalian cell lines, and in vivo, using zebrafish embryos. To establish safety margin, higher concentration of the protein (300 nM) was tested in both assays. In the MTT assay, which measures metabolic activity through the reduction of MTT to formazan by mitochondrial dehydrogenases, treatment with 300 nM LssR_M did not significantly affect cell viability in either cell line (Fig. 9A). This indicateed that LssR_M had no cytotoxic effects under the tested conditions, and it may be considered non-toxic. In the zebrafish model, exposure to 300 nM LssR_M showed no signs of acute toxicity. All embryos survived, and as controlled embryos, showed no observable developmental delay, blood coagulation, heart edema, or other malformations or signs of toxicity (Fig. 9B, C). Together, these in vitro and in vivo results strongly indicate that LssR_M is non-toxic at concentration of 300 nM, supporting the safe use of lower concentrations, such as 100 nM, in potential applications involving living organisms. Evaluation of LssR_M toxicity in vitro and in vivo. (A) Results of the MTT assay performed on human HaCaT keratinocytes and NIH 3T3 mouse fibroblasts exposed to 300 nM LssR_M for 22–24 h. Data from three independent experiments are presented as cell viability expressed as the percentage of the absorbance of the negative control (medium without LssR_M). (B) Lateral view of representative zebrafish embryos at 96 h post fertilization (hpf). Images show embryos treated with 300 nM LssR_M and untreated control. Scale bar = 1 mm. (C) Bar plot comparing the body length of zebrafish embryos treated for 4 days with 300 nM LssR_M and an untreated control. No significant difference in the body length was observed. For cell viability: *** - P < 0.001, two-way ANOVA with Sidak’s post-hoc multiple comparisons test, for body length: results not significant, unpaired t test. Discussion Antibiotic resistance and new antimicrobials With the growing challenge of antibiotic resistance and the scarcity of new antibiotics with novel mechanisms of action and low resistance prevalence, alternative antibacterial treatments are receiving increasing attention. Phage therapy, which has been explored for a long time for clinical implementation, represents one of such alternative approaches. Similarly, enzybiotics - peptidoglycan hydrolases with potent antibacterial activity - have been intensively studied in research laboratories and have recently advanced to clinical trials34. The importance of addressing resistance development in advance is a key lesson from the history of antibiotics. Consequently, the low prevalence of resistance is now among the most sought-after characteristics for new antimicrobials. In this context, bacteriolytic enzymes are considered a promising and safe option, as they are thought to be largely refractory to resistance development. However, despite this assumption, surprisingly little experimental evidence has been published to substantiate this claim35, 36. Lysostaphin is probably the best-characterised peptidoglycan hydrolase and has been extensively studied as an alternative to antibiotics4, 5. Despite its proven antistaphylococcal efficacy, the clinical application of lysostaphin faces significant challenges due to possible immune reactions, including the production of antibodies that reduce the treatment’s effectiveness and resistance mechanism already present in nature35, 37, 38. The immune response issue has been solved by the creation of deimmunized forms39, 40, 41. The resistance is still unsolved problem. Lysostaphin’s therapeutic potential is significant in terms of device-related infections. The enzyme’s ability to eradicate biofilms on surfaces could help the prevent difficult infections and suggest its potential as a prophylactic agent4, 13. Lysostaphin is produced by certain Staphylococcus simulans strains to serve as a potent weapon to eliminate competing staphylococci within the same ecological niche. To protect their own peptidoglycan, lysostaphin-producing strains replace some glycine residues with serine, rendering the cross-bridges resistant to lysostaphin. This immunity mechanism is encoded on a plasmid, enabling its easy horizontal transfer and facilitating the spread of lysostaphin resistance across various staphylococcal species, including Staphylococcus aureus15, 38. To address the challenge of lysostaphin resistance, we sought an enzyme with the bacteriolytic potential of lysostaphin but capable of cleaving cross-bridges containing serine, a feature that confers resistance to lysostaphin. Since S. simulans incorporates serine into its peptidoglycan cross-bridges, we hypothesized that it might produce a peptidoglycan hydrolase with specificity for such structures, serving as an autolysin. We have identified a novel enzyme, LssR, capable of lysing staphylococcal strains with serine-enriched peptidoglycan cross-bridges leading to the discovery of a novel M23 peptidase with the desired specificity in the S. simulans genome and proving our hypothesis correct. Potential of LssR in biomedical applications The demands set for new antimicrobials are very challenging. This is reflected in very few new antimicrobials being registered in the recent decades despite intense efforts put forth by researchers and pharmaceutical industry in this area. Apart from displaying low resistance prevalence, new antimicrobials should have high efficacy in bacterial elimination and sustain their activity and stability in natural, physiological conditions, being safe for humans, animals and environment at the same time. Our data demonstrate that both, the mature enzyme (LssR_M) and its catalytic domain (LssR_CD) exhibit robust lytic activity against staphylococcal strains, even the one containing pentaglycine or glycine/serine cross-bridges. Notably, the presence of serine in the cross-bridge - a known mechanism of lysostaphin resistance - did not substantially impair the lytic activity of LssR variants, distinguishing them from lysostaphin and AuresinePLUS. LssR_M displayed particularly broad functional flexibility, maintaining high activity across a range of pH values, temperatures, and ionic strengths, unlike LssR_CD, which efficiency was significantly reduced in high-salt environments and at suboptimal pH. This difference highlights the essential contribution of the cell wall-binding domain in stabilizing enzymatic function under physiologically variable conditions, in line with previous studies on modular endopeptidases27, 28. Temperature and pH profiles of LssR_M further support the practical versatility of LssR_M. The enzyme retained significant activity from room temperature up to 45°C, with optimal performance at 37°C, aligning with human body temperature. Even at 4°C, LssR_M retained measurable activity, which could be beneficial for applications requiring storage or function at low temperatures. The activity of LssR_M persisted even in complex biological matrices such as bovine and human serum, whereas lysostaphin and AuresinePLUS exhibited significant loss of activity against serine-substituted peptidoglycan. This serum tolerance is particularly relevant, as therapeutic enzymes targeting S. aureus must remain active in blood and tissue environments. Another expected feature of a new generation of antimicrobials is their defined, preferably narrow specificity. The screening of LssR_M activity across various bacterial strains highlights a relationship between the enzyme’s specificity and the composition and length of the peptidoglycan cross-bridge. This selectivity renders the enzyme highly effective against staphylococcal cells while leaving other bacterial strains unaffected. The efficacy among staphylococcal species varies, what provides an additional advantage of selective elimination of pathogenic species. This is particularly important for development of targeted therapies leading to the re-establishment of the balance in the skin microbiota which is strongly affected in many common skin disorders, like atopic dermatitis or psoriasis42. Safety evaluations confirmed that LssR_M is non-toxic at concentrations exceeding those effective for bacterial lysis. Both, in vitro tests on mammalian cell lines and in vivo experiments using zebrafish embryos revealed no signs of cytotoxicity or developmental defects, which supports its potential for therapeutic use. Collectively, these findings highlight LssR_M as a promising alternative to lysostaphin and related endopeptidases, particularly for treating infections caused by Staphylococcus strains incorporating serine into their peptidoglycan cross-bridges - a known mechanism of lysostaphin resistance31. The enzyme’s stability across physiologically relevant pH, temperature, and ionic conditions, coupled with serum tolerance and a favorable safety profile, emphasize its translational potential. Future work will focus on in vivo efficacy of LssR in the infection models. Materials and methods Bacterial strains All the bacterial strains used in this research, their sources and PGN (cross-bridge) composition are listed in Table 2. Table 2Bacterial strains used in the study.Bacterial strainCross-bridgeSourceStaphylococcus aureus NCTC 8325-4Gly5 43 Staphylococcus aureus TF5303Gly5 44 Staphylococcus aureus TF5311Gly/Ser 5–6 44 Staphylococcus aureus RN4220Gly5 45 Staphylococcus aureus RN4220 ΔtagOGly5 45 Staphylococcus cohni DSM20260Gly5DSMZStaphylococcus simulans DSM20322Gly5DSMZStaphylococcus simulans DSM20037Gly4-5-L-Ser1-2DSMZStaphylococcus simulans CCM3583Gly4-5-L-Ser1-2CCMStaphylococcus epidermidis DSM 20044Gly4-5-L-Ser1-2DSMZStaphylococcus intermedius DSM 20373Gly4-5-L-Ser1-2DSMZStaphylococcus capitis PCM2121Gly4-5-L-Ser1-2PCMSalinicoccus roseus CCM168Gly5-6CCMStaphylococcus haemolyticus PCM2113Gly4-5-L-Ser1-2PCMStaphylococcus warneri PCM2107Gly4-5-L-Ser1-2PCMBacillus subtilis IBB168DirectIBBStreptococcus agalactiae IBB130L-Ala2IBBCorynebacterium spp.Direct 50 Lactococcus lactis CCM1877D-AspCCMDSMZ - German Collection of Microorganisms and Cell Cultures; https://www.dsmz.de.CCM – Czech Collection of Microorganisms; https://ccm.sci.muni.cz/en.PCM – Polish Collection of Microorganisms; https://www.pcm.org.pl/home.IBB – Collection of Strains and Plasmids IBB PAS, Warsaw; https://ibb.edu.pl/central-services/kolekcja-szczepow-i-plazmidow/. Bacterial strains used in the study. DSMZ - German Collection of Microorganisms and Cell Cultures; https://www.dsmz.de. CCM – Czech Collection of Microorganisms; https://ccm.sci.muni.cz/en. PCM – Polish Collection of Microorganisms; https://www.pcm.org.pl/home. IBB – Collection of Strains and Plasmids IBB PAS, Warsaw; https://ibb.edu.pl/central-services/kolekcja-szczepow-i-plazmidow/. Gene identification The gene was identified in the S. simulans genome published with the NCBI Reference Sequence: NZ_CP014016.2. A BlastP search was performed using the protein sequence of a CD of the glycyl-glycine endopeptidase LytM46 as a query. A 424 amino acid protein was identified to be encoded by a gene with the reference code KXA44996.1. Cloning S. simulans (DSM 20322) was purchased from the German Collection of Microorganisms and Cell Cultures (DSMZ). Its genomic DNA was extracted using a bacterial genome isolation kit (A&A Biotechnology, Gdynia, Poland). A signal peptide was recognized using SignalP-6.017 and excluded from cloning. Three gene variants were amplified by polymerase chain reaction using primers presented in Table S1. Two expression vectors linearized by polymerase chain reaction were used: pMCSG7 with an N-terminal His6-tag followed by the TEV cleavage site and pMCSG9 with an N-terminal His6-tag and maltose-binding protein (MBP) followed by the TEV cleavage site (Midwest Center for Structural Genomics, USA). The amplified DNA fragments were cloned into the vectors by the ligase-independent cloning method (LIC)47. The resulting plasmids were verified by sequencing. Expression and preliminary purification of proteins The competent cells E. coli BL21 Gold with kanamycin resistance were used as an expression host. For test purification, the overnight LB-ampicillin-kanamycin cultures were refreshed by dilution at a 1:20 ratio in 5 ml of fresh media and propagated at 37°C for three hours to an OD600 of ~ 1. Isopropyl-β-D-thiogalactopyranoside (IPTG, Merck, USA) was added to a final concentration of 1 mM, and the culture was grown for three hours at 37°C. Cells were harvested by centrifugation at 4,000 x g for 30 min at 4°C, resuspended in 1 ml of binding buffer (50 mM Tris-HCl pH 8.0, 500 mM NaCl, 20 mM imidazole) and disrupted using the freeze-thaw lysis method. Clarified lysate was mixed with 50 µl of HisTrap HP (GE Healthcare, USA) resins equilibrated with binding buffer. The resin-bound proteins were washed three times with 0.5 ml of binding buffer. The proteins were eluted with 100 µl of elution buffer (50 mM Tris-HCl pH 8.0, 500 mM NaCl, 300 mM imidazole). The samples from consecutive purification steps were analysed by SDS-PAGE gels to assess the quality and quantity of the protein. The constructs for large-scale purification were chosen based on the preliminary purification results and the protocol was further optimized. Large scale protein production For large-scale purification, the proteins were expressed in E. coli BL21 Magic cells in LB medium supplemented with 100 µg/ml ampicillin and 50 µg/ml kanamycin. When the bacterial cultures reached OD600 of ~ 1.0, they were cooled to 18°C and IPTG was added to a final concentration of 1 mM. The cultures were kept at 18°C for 16 h with constant shaking. Cells were harvested by centrifugation at 4,000 x g for 30 min at 4°C and resuspended in 80 ml of binding buffer (50 mM MES pH 6.2, 500 mM NaCl, 20 mM imidazole). Nuclease (Viscolase, A&A Biotechnology, Poland) was added to the final concentration of 12.5 U/ml. The cells were disrupted by sonication and the lysates were clarified by centrifugation at 100,000 × g for 45 min at 4°C. Supernatants were filtered through 0.45 μm membrane and run through the 5 ml HisTrap prepacked columns (BabyBio, Bio-Works, Sweden). The resin-bound molecules were washed with 40 ml of the binding buffer. The target proteins were eluted with 20 ml of elution buffer (50 mM MES pH 6.2, 500 mM NaCl, 300 mM imidazole). Overnight dialysis of the eluted protein was performed at 4°C against the binding buffer to lower the imidazole concentration. Simultaneously, TEV protease was added to a final concentration of 0.05 mg/ml to cut off the His6-tag from LssR_FL and LssR_M, and His6-tag-MBP fusion protein from LssR_CD. A protein mixture was applied onto a HisTrap column to capture any nondigested tagged protein and TEV protease. The flow through was collected, transferred onto the 10 kDa cut-off (MWCO) Amicon Ultra centrifugal filters and concentrated at 4°C. The protein samples were applied onto a HiLoad 16/600 Superdex 75 pg (GE Healthcare, USA), equilibrated with SEC buffer composed of 20 mM MES pH 6.2, 200 mM NaCl, and 10% glycerol. The fractions with purified proteins were pooled together and concentrated using Amicon Ultra centrifugal filters (Merck). The protein concentration was determined from the absorption measured at 280 nm using a UV spectrophotometer. The molar extinction coefficient [ε] was calculated using the ProtParam tool on the ExPasy server48 to be 71,740 M-1 x cm-1 for LssR_FL, 64,290 M-1 x cm-1 for LssR_M, and 32,890 M-1 x cm-1 for LssR_CD. Lysostaphin used in the assays for comparisons was produced as described previously9. Enzymatic and bacteriolytic activity assays The bacteriolytic activities of the various forms of the investigated protein were determined by monitoring the optical density change of a bacterial cell suspension in a turbidity reduction assay (TRA) and by determination of the colony-forming units (CFU). Turbidity reduction assay. All bacterial strains stored as glycerol stocks at – 80°C were refreshed on tryptic soy broth (TSB) agar plates. A single colony was taken from a TSB agar plate and cultured overnight at 37°C in a TSB medium, supplemented with 30 µg/ml of chloramphenicol for S. aureus strains TF5303 and TF5311, or 2.5 µg/ml erythromycin for S. aureus RN4220ΔtagO strain. The cultures were refreshed and collected in the logarithmic phase, when they reached OD595 of ~ 0.6–0.8. The assay was carried out in two buffers: a low ionic strength buffer composed of 50 mM glycine (pH 8.0) and a high ionic strength buffer composed of 50 mM glycine (pH 8.0) and 200 mM NaCl. Pellets were resuspended to OD595 of 1.0 in the reaction buffer, 100 µl of this suspension was transferred onto each well of a microtiter plate and mixed with 100 µl of the tested enzyme (50 to 200 nM) in the reaction buffer. For a negative control, the bacteria were suspended in the reaction buffers with no enzyme added. OD595 was monitored for a given time at room temperature, with measurements taken at least every 10 min, after the initial 5 s mixing (T0). The results are presented as reduction of optical density measured at 595 nm and calculated as the percent of the control (without enzyme) or normalized to indicated value. Each assay was done in technical triplicates and biological triplicates which were different bacterial cultures. CFU determination. The bacterial cells of both S. aureus 8325-4 and S. simulans CCM3583 were grown, collected, and resuspended as described in the Turbidity reduction assay section. The tested enzymes were added at 50 nM, 100 nM, and 200 nM concentrations, and the reaction was incubated at 21°C. The samples were collected at defined time points. As a control, a bacterial suspension supplemented with buffer without enzyme was used. Serial dilutions of reaction mixtures were prepared and plated on TSB-agar plates. The number of colonies was counted after overnight incubation at 37°C and the CFU/ml was calculated. The CFU reduction was determined based on the difference between the control and the sample at particular time points. The experiment was performed twice. Peptidoglycan digestion analysis S. aureus NCTC 8325-4 and S. capitis CCM3583 peptidoglycan isolations were performed based on the protocol described by de Jonge et al.49. Isolated material was resuspended in 50 mM glycine buffer, pH 8.0 supplemented with 100 mM NaCl and treated with 0.5 U/µl mutanolysin (A&A Biotechnology) at 50°C for 24 h. Then each peptidoglycan was treated with 1 µM LssR_M at room temperature for 24 h. Samples were reduced with 0.5 M borate buffer, pH 9.0 containing 2.94 mg/ml sodium borohydride. After 30 min of incubation at room temperature, pH was adjusted to 2.0 using orthophosphoric acid and the samples were centrifuged at 20,000 x g at room temperature for 5 min. Obtained supernatants were then separated on an Acquity UPLC Protein BEH C4 column (Waters) in a gradient of 0.1% formic acid in H2O and 0.1% formic acid in acetonitrile and analysed on a Synapt G2 mass spectrometer (Waters) with electrospray ionization in positive mode and time-of-flight analyser. Mass spectrometry data were analysed using MassLynx V4.1 software (Waters). Activity in serum LssR_M enzyme activity in fetal bovine, human, horse and rabbit serum (Merck, USA) was determined and compared to lysostaphin and AuresinePLUS chimeric enzyme27 activities by determination of CFU after treatment. S. aureus TF5303, TF5311 and S. simulans CCM3583 strains at initial 106 CFU/ml were incubated with 100 nM enzymes either in a control 50 mM glycine pH 8.0, 100 mM NaCl buffer or serum for 4 h at 37°C. Bacterial cell numbers were determined by plating serial dilutions. Results are presented as log10 decrease (mean ± SD). Optimal pH, temperature and chelating agents analysis Turbidity recuction assays were run to evaluate the effect of pH, temperature, and chelators on enzymes activity as described above. The influence of pH on enzymatic activity was tested for a range of buffers with a constant conductivity of ~ 2 mS/cm and broad range of pH: citrate pH 5.4, MES pH 6.0, Tris-HCl pH 7.0, Tris-HCl pH 8.0, Tris-HCl pH 9.0, CAPS pH 10.0, and CAPS pH 10.9. The effect of temperature was measured at 4, 21, 37 and 45°C. To evaluate the effect of chelating agents, both EDTA at a concentration from 0.6 to 250 mM and phenanthroline at a concentration from 0.12 to 2 mM, were examined. Tests were done in 50 mM glycine buffer, pH 8.0 for LsSR_CD and the same buffer additionally supplemented with 100 mM for LssR_M . Both enzymes were used at the final concentration of 100 nM. Safety assessment In vitro toxicity test: mice fibroblasts (NIH 3T3 cell line) and human keratinocytes (HaCaT cell line) were cultured in DMEM medium (Gibco) supplemented with 10% Fetal Bovine Serum (FBS; Gibco) and 1% Penicillin-Streptomycin (Gibco). Cells were maintained at 37 °C in a 5% CO2 atmosphere (Memmert incubator). Cultures were kept in 9 cm Ø tissue culture dishes (VWR) and subcultured 2–3 times per week. All experiments were performed using cells at approximately 80% confluency from passages < 7. Prior to the MTT assay, cells were washed with 10 ml of Phosphate Buffered Saline (PBS, Sigma), and detached using 1–2 ml of TrypLE Express (Gibco) followed by gentle tapping the dish. Once the cells dislodged and no adhered cells remained visible on the dish surface, an equal volume of phenol red-free and antibiotic-free DMEM medium (Gibco, 21063-029) supplemented with 10% FBS was added. The cell suspension was gently pipetted up and down to break up any cell clumps. Cell counts and viability were assessed using Countess™ benchtop cell counting system (Invitrogen) and EVE™ cell counting slides (NanoEnTek), according to the manufacturer’s guidelines. Cell density was adjusted to 5 × 105 cells/ml in phenol red–free and antibiotic-free DMEM medium with 10% FBS. A 100 µl aliquots of the cell suspension were seeded into a 96-well plate (NEST Cell Culture Plate, Polysteryne, Non-Pyrogenic). For background control, wells were filled with an equal volume of medium. The following day, the medium was replaced with fresh, filtered (through a 0.22 μm syringe filter, Avantor) DMEM supplemented with 10% FBS only (control) or 10% FBS and 300 nM LssR_M (treatment), and cells were allowed to grow for an additional 22–24 h. To assess cell viability, 10 µl of thiazolyl blue tetrazolium bromide (MTT, POL-AURA) was added to each well to achieve a final concentration of 0.5 mg/ml. Plates were incubated at 37°C for additional 2 h. Subsequently, 100 µl of dimethyl sulfoxide (DMSO, POL-AURA) was added to each well directly to the medium, and the plates were left to incubate for approximately 30 min at room temperature with gentle agitation. Once formazan crystals were fully dissolved, the absorbance was measured at 570 nm using a Multiskan FC spectrophotometer (ThermoScientific). In vivo toxicity test: wild type ABOMD zebrafish (Danio rerio) line was housed and bred at the fish facility of the Mossakowski Medical Research Institute, Polish Academy of Sciences. All experiments were carried out in compliance with national legislation and the guidelines outlined in European Directive 2010/63/EU. Ethical approval was not required for this stage of the study, as it involved only early developmental stages of zebrafish (up to 5 days post-fertilization), which are not covered by current EU regulations on animal experimentation. Embryos from spontaneous group mating were collected using a tea strainer, washed with tap water, and transferred to a Petri dish with E3 medium (a standard zebrafish medium composed of aqueous solution of 5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, 0.33 mM MgSO4; with pH adjusted to 7.0). Only clutches with > 90% of fertilized and well-developing eggs were selected for the experiments. Groups of 12 high-quality embryos were transferred to 3 cm Ø Petri dishes, and 2 ml of E3 medium was added to each dish. Prior to reaching the blastula stage, the medium was replaced with either 2 ml of fresh E3 medium (control) or 2 ml of fresh E3 medium complemented with 300 nM LssR_M (treatment). The embryos were then incubated at 28°C for four days. The medium was refreshed daily (with or without enzyme), and the embryos were assessed under a stereoscope (Zeiss, Stemi 508) for survival, developmental delay, blood coagulation, heart edema, and other morphological malformations. The tests were conducted with three biological replicates. Statistical analysis Data analysis was carried out using GraphPad Prism software version 8.0.2. For the details concerning the tests used, see description under each of the figures. Data is presented as a mean ± standard deviation. The differences were considered significant at P < 0.05. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements We would like to acknowledge Prof. Andreas Peschel for kindly sharing all the WTA mutants belonging to the University of Tübingen Microbial Collection, Motoyuki Sugai from Hiroshima University for sharing S. aureus strains TF5303, and TF5311, IBB PAN (Warsaw, Poland) for sharing some of the bacterial strains from their central collection of strains, and Dr. Maria Małecka for performing thermal shift assay at the BioLab operated by the Helmholtz-Zentrum Berlin für Materialien und Energie. Author contributions Małecki P.H. – gene identification, cloning, initial protein purification, protocol optimization, structural analysis, activity and stability tests, compiling results, manuscript writing and revision. Trochimiak K. – protein purification, protocol optimization, activity and stability tests, compiling results. Jagielska E. – analysis of activity in serum, manuscript writing, and revision. Zaród M. – determination of the enzyme cleavage site, statistical analysis. Korzeniowska M. – designing and conducting toxicity tests, compiling results. Augustyniak W. – conducting activity tests in serum. Sabała I. – experimental approach design, data analysis and interpretation, project supervision, manuscript writing and revision. Funding This work was supported by the Foundation for Polish Science (FNP) programs co-financed by the European Union under the European Regional Development Fund (grant number POIR.04.04.00–00–3D8D/16–00) and the Medical Research Agency (PL) (grant number KPOD.07.07-IW.07–0030/24). Data availability All data supporting the findings of this study are available within the paper and its Supplementary Information. Declarations Competing interests PHM, IS, EJ, KT, WA are inventors of the patent PL243 304 B1 and patent application WO2021075988A1. Ethical approval As per the European Directive 2010/63/EU and the national act of January 15, 2025, on the Protection of Animals Used for Scientific or Educational Purposes, zebrafish embryos/larvae up to 120 h post-fertilization are not classified as protected animals, the experiments described in this study did not require approval from the local ethics committee. However, all efforts were made to ensure humane treatment of the embryos, minimize stress or harm. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement All data supporting the findings of this study are available within the paper and its Supplementary Information.